Victoria Vakiener Sells 1,799 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Victoria Vakiener sold 1,799 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total value of $41,934.69. Following the completion of the sale, the director now owns 30,205 shares in the company, valued at $704,078.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR opened at $25.00 on Wednesday. Arrowhead Pharmaceuticals, Inc. has a one year low of $20.67 and a one year high of $41.36. The company has a 50-day simple moving average of $27.10 and a 200-day simple moving average of $28.74. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of -8.99 and a beta of 0.78.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.46). The company had revenue of $3.55 million for the quarter, compared to analysts’ expectations of $35.60 million. Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 90.77%. The firm’s revenue was down 94.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.39) earnings per share. As a group, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ARWR shares. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Citigroup upped their target price on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a report on Wednesday, February 7th. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, February 8th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $50.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $50.80.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Large investors have recently modified their holdings of the stock. Washington Trust Advisors Inc. purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $25,000. Fifth Third Bancorp raised its holdings in Arrowhead Pharmaceuticals by 112.0% during the third quarter. Fifth Third Bancorp now owns 988 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 522 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at about $41,000. Quest Partners LLC purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $45,000. Finally, Friedenthal Financial acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $51,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.